Hobart Private Capital, LLC Gilead Sciences, Inc. Transaction History

Hobart Private Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Mar 11, 2024	SELL	$67.69 - $73.03 $269,135 - $290,367	-3,976 Closed	0 $0
Q2 2021 Mar 11, 2024	SELL	$63.47 - $69.35 $16,819 - $18,377	-265 Reduced 6.25%	3,976 $274 Million
Q1 2021 Mar 11, 2024	BUY	$60.0 - $68.46 $254,460 - $290,338	4,241 New	4,241 $274 Million
Q4 2020 Mar 11, 2024	SELL	$56.65 - $64.55 $471,781 - $537,572	-8,328 Reduced 53.74%	7,170 $418 Million
Q3 2020 Mar 11, 2024	BUY	$62.1 - $78.08 $641,741 - $806,878	10,334 Added 200.12%	15,498 $979 Million
Q2 2020 Mar 11, 2024	SELL	$72.34 - $84.0 $1.16 Million - $1.34 Million	-16,010 Reduced 75.61%	5,164 $397 Million
Q1 2020 Mar 11, 2024	BUY	$62.63 - $80.22 $122,880 - $157,391	1,962 Added 10.21%	21,174 $1.58 Billion
Q4 2019 Mar 11, 2024	BUY	$61.62 - $67.78 $1.18 Million - $1.3 Million	19,212 New	19,212 $1.25 Billion
Q3 2019 Mar 11, 2024	BUY	$62.51 - $69.0 $1.14 Million - $1.25 Million	18,162 New	18,162 $1.15 Billion

1,924

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Hobart Private Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Hobart Private Capital, LLC with notifications on news.